Multiple Catalysts Ahead For Nektar Therapeutics
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook
Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Nektar Therapeutics Reports Stable Q3 Earnings for 2024
Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Looking ahead, ...
Seeking Alpha6d
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
Good day and thank you for standing by. Welcome to the Nektar Therapeutics' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
ETF Daily News7d
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at Piper Sandler
Piper Sandler assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research note released on Monday, Marketbeat Ratings reports. The brokerage issued an overweight ...